Guardion Health Sciences — Investor Presentation (April 2020)
28 slides from Guardion Health Sciences's investor presentation, Apr 21, 2020
Slide 1: Changing the Course of Eye Care
NASDAQ: GHSI GUARDION ~ HEALTH SCIENCES . Changing the Course of Eye Care guardionhealth.com
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation may contain forward-looking statements within the meaning of Section 27 A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are characterized by future or conditional verbs such as "may," "wil
Slide 3: Guardion at a Glance
Guardion ata Glance Formed as an ocular health sciences company Develops, formulates, manufactures and distributes condition-specific medical food, devices and nutraceuticals Supported by evidence-based protocols Devices VECTORVISION’ Transcranial Doppler Solutions Ocular Blood Flow NM NutriGuard Im
Slide 4: Projected every four minutes, one American will experience sight loss
“It is projected that every four minutes, one American will experience partial or complete loss of sight. The need to confront preventable blindness has never been more urgent.” National Academics of Sciences, Engineering, and Medicine ©) GUARDION
Slide 5: Macular Protective Pigment (MPP)
Macular Protective Pigment (MPP) Critical fo Ocular Health Absorbs Harmful Blue Light Plays a Critical Role in: Blue Light Sources eooat Average Americans spend ~11 hours per day looking at a screen! Visual acuity Contrast sensitivity Light sensitivity > 1: Qt 2018 Nielsen Total Audience Report
Slide 6: Macular Protective Pigment
Macular Protective Pigment Low Levels Are Key Risk Factor in AMD Age-Related Macular Degeneration (AMD) is the Leading Cause of Vision Loss Over Age 55 MPP Shields Retina Depleted MPP Puts from Harmful Light Retina at Risk for Damage .@> GUARDION HEALTH SCIENCES.
Slide 7: Eye Care Market Opportunity
Eye Care Market Opportunity AMD Glaucoma ~11 million ~196 million ~3 million ~60 million people in U.S! people worldwide’ people in U.S? people worldwide? 1: https:/Awww. brightfocus.org/macular/articlefage-related-macular-facts-figures 7 > 2: https www brightfocus org/glaucomavarticle/glaucoma-fact
Slide 8: Nutraceutical Market Opportunity
Nutraceutical Market Opportunity © AAA 4 Ability to develop Ability to modify Provides Direct products specific formulations to adapt to to Consumer to conditions changing market conditions (DTC) Marketing HEALTH SCIENCES.
Slide 9: Current Standard of Care Is Lacking
Current Standard of Care Is Lacking Current tests are not standardized, and lack Currently no effective treatment accuracy and repeatability \ 4 Primary treatment is to lower eye ‘ ‘ fi y Current tests often detect Eee ue ne cyecive poaunent I Y 1d y ae for patients who continue to lose > . a U (Ss
Slide 10: Medical Foods
Medical Foods Prescription Supplements drugs OTC drugs Self-diagnosis Vitamins Nutraceuticals Functional foods medication Less Regulation More Regulation Medical Foods Are a Distinct FDA Regulated Category, Separate From Dietary Supplements and Pharmaceuticals HEALTH SCIENCES.
Slide 11: Strategy Focused on Early Detection, Intervention & Monitoring
Strategy Focused on Early Detection, Intervention & Monitoring SO LUMEG. Glauce i NutriGuard Immune Support Complex Medical Foods VECTORVISION’ mejecats F Transcranial Doppler Solutions Ocular Blood Flow
Slide 12: LUMEGA-Z
LUMEGA-Z Vision-Specific Medical Food Nutritional intervention shown to support ocular health Unique lipid-based liquid delivery system, providing maximum absorption and bioavailability In a head-to-head comparison between Lumega-Z and PreserVision, a clinical study measured the bioavailability of c
Slide 13: LUMEGA-Z: Improvement in Visual Function in AMD Patients
LUMEGA-Z Statistically Significant Improvement in Visual Function In AMD Patients With Drusen In a recent study (n=79) presented at ARVO: Statistically Significant Improvement in Visual Function Over AREDS 2 Lumega-Z demonstrated significant improvement 135 (p<0.001) in Contrast Sensitivity visual f
Slide 14: LUMEGA-Z: Improvement in Central Visual Field in Glaucoma
LUMEGA-Z Significant Improvement In Central Visual Field In Patients With lOP Stabilized Glaucoma Lumega-Z was associated with significant improvement in FDT pericentral function among patients with severe glaucoma who had previously shown degeneration despite having had excellent intraocular pressu
Slide 15: GlaucoCetin
GlaucoCetin Vision-Specific Medical Food GlaucoCetin has been formulated with the Designed to support healthy Optic Nerve Cells specific compounds that have been shown to improve mitochondrial dysfunction and are associated with neuroprotective activity’ Shown to improve blood flow in the ophthalmic
Slide 16: NutriGuard
NutriGuard Condition Specific Nutraceuticals Made in the United States utilizing premium quality ingredients Rigorous manufacturing and quality assurance standards to include cGMP and NSF approved facilities Designed to Supplement Diets and Assist in the Support of a Healthy Lifestyle HEALTH SCIENCE
Slide 17: VectorVision
VectorVision Visual Testing Only All-In-One Digital Vision Tester : with Standardized Contrast Sensitivity, Letineninlg Setoue Geneve : é CSV-2000 imminently Glare and Visual Acuity i Current CSV-1000 is standard for FDA clinical trials and is used clinically in more than 60 countries Recognized sta
Slide 18: MapcatSF
MapcatSF Visual Testing Provides Quick, Easy, Accurate and Repeatable Test to Measure the Macular Pigment Optical Density (MPOD) Measures macular pigment density by amount of blue light radiation being absorbed Ability to determine blue light absorption of macular pigment vs. lens .@ GUARDION (3 HEA
Slide 19: Transcranial Doppler Solutions
Transcranial Doppler Solutions Ocular Blood Flow Safe, Non-Invasive Device to Assess Intracerebral Blood Flow, Within the Brain and to the Eyes Measures changes in ophthalmic artery blood flow to help evaluate the course of common eye disorders Also has the ability to predict stroke risks as well as
Slide 20: Leveraging Multiple Sales Routes
Leveraging Multiple Sales Routes Medical Foods Partnered with Eye Doctors | Physician Recommended We suiee Ses In-Office Testing Days (Test patients using portfolio of devices) Direct to Consumer O=U Cl Online Sales Oy Subscriptions @) Devices WY <= = Small Dedicated Sales Force Tradeshows and Confe
Slide 21: Diagnostics Drive Sales for Medical Foods
Diagnostics Drive Sales for Medical Foods Diagnostics Equipment Medical Foods VECTORVISION | mecatsF’ HOH onan , (sz) ad IUMEGA 8 5 Medical Food Re) VECTORVISION” Transcranial Doppler Solutions = a Ocular Blood Flow a 5 Glauce@etin / po ee GUARDION
Slide 22: Leadership Team
Leadership Team £ Michael Favish David W. Evans, PhD John Townsend Susan Klein, ND Vincent J. Roth President & CEO, Director Director, Chief Accounting Officer Director of Esq., General Counsel Chief Science Officer Medical Education (iz ‘= ie Robert N. Weingarten Mark Goldstone Kelly J. Anderson Do
Slide 23: Science Advisory Board
Science Advisory Board Product Development and Research Team of Recognized Experts in the Fields of Biochemistry, Biophysics and Clinical Nutrition Richard A. Bone, BSc, PhD, FARVO Distinguished experimental biophysicist and professor in the department of physics at Florida International University
Slide 24: Medical Advisory Board
Medical Advisory Board Internationally Renowned Clinicians Who Are Active Medical Practitioners Robert Ritch, MD William Trattler, MD * Holds the Shelley and Steven Einhorn Distinguished Chair in Ophthalmology Received the “Outstanding Young Ophthalmologist Leadership Award” from : and is Surgeon Di
Slide 25: Financial Snapshot
Financial Snapshot: NASDAQ: GHSI Market Cap! Avg. 3m Shares Daily Shares Outstanding Trading Volume! $11.2M Cash Balance as of 12/31/2019 Does not include proceeds from ~$3.5M Warrant Exercise on 3/5/2020 @) 1: Based on Apiil 7, 2020 closing price of $.44 per share GUARDION HEALTH SCIENCES.
Slide 26: Value Driving Milestones
Value Driving Milestones Generation VectorVision® Under Newly Acquired NutriGuard Corporate Apply Unique Practice Development and Digital Strategies to Increase Database of Clients Launch Second Develop Nutraceutical Product Line Qi 2020 Launch Robust Penetrate Medical Marketing Campaign Foods Natio
Slide 27: Investment Opportunity
Investment Opportunity Robust Portfolio of Medical Foods and Devices to Support Ocular and Overall Health (6) “al Evidence-Based Protocols Launching Robust Effort to Focused on Early Detection, Grow Existing Accounts and Intervention and Monitoring Reach New Customers
Slide 28: Changing the Course of Eye Care
NASDAQ: GHSI HEALTH SCIENCES | Changing the Course of Eye Care Investor Relations: JTC Team, LLC 833-475-8247 j ghsi@jtcir.com a guardionhealth.com
Guardion Health Sciences — Investor Presentation (April 2020) on 6ix